GenSight Biologics: Funding, Investors & Team (Sep 2026)
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
GenSight Biologics has raised $72.1M across 10 funding rounds on record, the most recent an undisclosed round of $2.0M announced in Mar 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GenSight Biologics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
GenSight Biologics Funding Rounds
GenSight Biologics raised $5.1M in an undisclosed round announced in Nov 2023.
3 months later, an undisclosed round of $5.4M was announced in Feb 2024.
3 months later, an undisclosed round of $10.0M was announced in May 2024.
6 months later, an undisclosed round of $3.0M was announced in Nov 2024.
4 months later, an undisclosed round of $930k was announced in Mar 2025.
4 months later, an undisclosed round of $580k was announced in Jul 2025.
5 months later, an undisclosed round of $3.4M was announced in Dec 2025.
3 months later, an undisclosed round of $2.0M was announced in Mar 2026.
GenSight Biologics Founders and Leadership Team
Contact details for the GenSight Biologics team: 3 of 3 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →GenSight Biologics Funding Compared to Other Biotechnology Startups
GenSight Biologics' latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GenSight Biologics in Biotechnology and Paris
Companies Similar to GenSight Biologics
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
GenSight Biologics Funding FAQs
What does GenSight Biologics do?
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
How much funding has GenSight Biologics raised?
GenSight Biologics has raised $72.1M across 10 rounds on record. The most recent is an undisclosed round of $2.0M announced in Mar 2026.
When did GenSight Biologics last raise funding?
GenSight Biologics' most recent funding round on record is an undisclosed round of $2.0M, announced in Mar 2026.
Who founded GenSight Biologics?
FundedIQ lists Bernard Gilly (Founder), Laurence Rodriguez (Founder), Luk Vandenberghe (Founder) at GenSight Biologics.
Where is GenSight Biologics headquartered?
GenSight Biologics is based in Paris, Ile-De-France, France.
How many employees does GenSight Biologics have?
GenSight Biologics is in the 11-50 employee band.
How does GenSight Biologics' funding compare to other Biotechnology startups?
GenSight Biologics' latest round of $2.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's GenSight Biologics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GenSight Biologics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.